Related Experiment Video

Updated: May 21, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Overcoming treatment resistance in HER2-positive breast cancer: potential strategies

Fabio Puglisi1, Alessandro Marco Minisini, Carmine De Angelis

  • 1Department of Oncology, University Hospital of Udine, Udine, Italy. fabio.puglisi@uniud.it

Drugs
|June 13, 2012
PubMed

Insights

Anti-HER2 treatments improve outcomes for HER2-positive breast cancer. However, resistance mechanisms like PI3K/AKT pathway amplification necessitate new strategies, including pertuzumab and mTOR inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • HER2 overexpression in 20% of breast cancers leads to poor prognosis.
  • Anti-HER2 therapies like trastuzumab and lapatinib have improved outcomes for HER2-positive breast cancer.
  • Resistance to these therapies is a significant clinical challenge.

Purpose of the Study:

  • To review current anti-HER2 treatments for breast cancer.
  • To elucidate mechanisms of resistance to trastuzumab and lapatinib.
  • To discuss emerging strategies for overcoming anti-HER2 treatment resistance.

Main Methods:

  • Literature review of anti-HER2 therapies and resistance mechanisms.
  • Analysis of pathways involved in HER2 signaling and resistance.
  • Examination of novel therapeutic strategies in development.

Main Results:

  • Trastuzumab and lapatinib are effective but resistance develops.
  • Resistance mechanisms include receptor crosstalk, PI3K/AKT pathway amplification, and altered HER2 binding or expression.
  • Compensatory pathways like PI3K/AKT and ER signaling contribute to lapatinib resistance.

Conclusions:

  • Overcoming resistance is crucial for improving patient outcomes in HER2-positive breast cancer.
  • New agents like pertuzumab, T-DM1, and mTOR inhibitors show promise in preclinical and clinical studies.
  • Targeting resistance pathways offers a path toward more effective and durable responses to anti-HER2 therapy.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...